Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Jacobs

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Medicine|April 1, 2022
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adultsBen Killingley, Alex J Mann, Mariya Kalinova, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Trials|July 27, 2021
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letterGareth O Griffiths, Richard FitzGerald, Thomas Jaki, et al.
Lancet (London, England)|May 23, 2016
Late Ebola virus relapse causing meningoencephalitis: a case reportMichael Jacobs, Alison Rodger, David J Bell, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Genome Biology|June 7, 2007
Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strainsLaurence Rohmer, Christine Fong, Simone Abmayr, et al.
Lancet (London, England)|October 22, 2017
Evidence-based guidelines for supportive care of patients with Ebola virus diseaseFrançois Lamontagne, Robert A Fowler, Neill K Adhikari, et al.
European Heart Journal|February 17, 2021
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonanceTushar Kotecha, Daniel S Knight, Yousuf Razvi, et al.
ERJ Open Research|September 23, 2020
Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocolAlexander G Mathioudakis, Fekri Abroug, Alvar Agusti, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
Nature Medicine|April 1, 2022
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adultsBen Killingley, Alex J Mann, Mariya Kalinova, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
Trials|July 27, 2021
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letterGareth O Griffiths, Richard FitzGerald, Thomas Jaki, et al.
Lancet (London, England)|May 23, 2016
Late Ebola virus relapse causing meningoencephalitis: a case reportMichael Jacobs, Alison Rodger, David J Bell, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Genome Biology|June 7, 2007
Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strainsLaurence Rohmer, Christine Fong, Simone Abmayr, et al.
Lancet (London, England)|October 22, 2017
Evidence-based guidelines for supportive care of patients with Ebola virus diseaseFrançois Lamontagne, Robert A Fowler, Neill K Adhikari, et al.
European Heart Journal|February 17, 2021
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonanceTushar Kotecha, Daniel S Knight, Yousuf Razvi, et al.
ERJ Open Research|September 23, 2020
Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocolAlexander G Mathioudakis, Fekri Abroug, Alvar Agusti, et al.
Pageof 20